U.S. Markets closed

Idera Pharmaceuticals, Inc. (IDRA)


NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
1.93+0.20 (+11.56%)
At close: 4:00PM EDT
People also watch
CPRXFOLDHALOCLDXGALE

Idera Pharmaceuticals, Inc.

167 Sidney Street
Cambridge, MA 02139
United States
617-679-5500
http://www.iderapharma.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees62

Key Executives

NameTitlePayExercisedAge
Mr. Vincent J. MilanoChief Exec. Officer, Pres and Director843.24kN/A53
Mr. Louis J. Arcudi III, MBAChief Financial Officer, Sr. VP of Operations, Treasurer and Assistant Sec.490.54kN/A56
Mr. Mark J. Casey Esq.Sr. VP, Gen. Counsel and Sec.518.64kN/A54
Mr. Robert Clayton FletcherSr. VP of Bus. Devel. & Strategic Planning513.24kN/A54
Dr. Sudhir Agrawal D.Phil., F.R.S.C.Pres of Research and Director828.08kN/A63
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the United States. It uses two drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and third-generation antisense (3GA) technology. The company’s drug candidates include IMO-2125, an agonist that is in Phase I/II clinical trials in combination with ipilimumab and pembrolizumab for the treatment of anti-PD-1 refractory metastatic melanoma and refractory solid tumors; IMO-8400, an antagonist, which is in Phase II clinical trial for the treatment of dermatomyositis. It also develops IDRA-008 for undisclosed liver target for rare disorder; 3GA compound for renal target; and IMO-9200, a drug candidate for potential use in selected autoimmune disease indications. In addition, the company is developing drug candidates to turn off the messenger RNA associated with disease causing genes. Idera Pharmaceuticals, Inc. has collaboration and license agreement with GSK to research, develop, and commercialize selected molecules from its 3GA technology for the treatment of selected targets in renal disease; collaboration with Abbott Molecular Inc. for the development of an in vitro companion diagnostic; and Merck & Co to research, develop, and commercialize vaccine products. The company was founded in 1989 and is based in Cambridge, Massachusetts.

Corporate Governance

Idera Pharmaceuticals, Inc.’s ISS Governance QualityScore as of June 2, 2017 is 6. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 10; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.